<DOC>
	<DOCNO>NCT00172367</DOCNO>
	<brief_summary>Primary Objective : To study lycopene improve biomarker status urothelial cell patient uremia-associated urothelial carcinoma . Secondary Objective : To evaluate general safety tolerability oral lycopene 30 mg per day 12 week uremic patient .</brief_summary>
	<brief_title>Chemoprevention Trial Uremia-Associated Urothelial Carcinoma</brief_title>
	<detailed_description>This renal function-stratified phase II chemoprevention trial . After 8 week run-in washout period , participant take lycopene , 30 mg per day 12 week . The expression intermediate biomarkers determine upon study entry 8 week run-in/washout , 6 12 week lycopene supplementation . It take least 20 week complete course .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Lycopene</mesh_term>
	<criteria>Patients pathologicallyproven urothelial carcinoma ( UC ) clinical stage &lt; = T3N0M0 Patients visible identifiable residual UC treatment life expectancy &gt; 6 month Patients remain urothelium risk recurrence ( transplanted renal unit exclude ) No active malignancy . Patients primary malignancy treat successfully prior study entry cure remission state least one year . Patients able take lycopene capsule orally . Patients sign give informed consent willing conform schedule sample blood , urine and/or tissue Patients clinical stage &gt; T3N0M0 metastatic disease Positive urine cytology . Patients positive cytology subject serial diagnostic workup may include renal echo , cystoscopy ureterorenoscopy , image study ( intravenous urography , compute tomography , magnetic resonance urography , retrograde antegrade pyelography ) . If recurrent residual tumor find , patient still eligible study . Patients ever receive systemic chemotherapy within 12 month Patients gastrointestinal malabsorption regardless etiology Have know allergic reaction tomato lycopene Patients participate participate clinical trial Patients active urinary tract infection accrue infection effectively control Patient 's age le 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Lycopene</keyword>
	<keyword>uremia</keyword>
	<keyword>prevention</keyword>
	<keyword>biomarker</keyword>
	<keyword>progression</keyword>
	<keyword>anti-oxidant</keyword>
</DOC>